

### **Remarks**

Claims 1-8, 10-12, 14-23, 28, and 31 have been amended without any intention of disclaiming equivalents thereof. Claims 9, 13, 24-27, 29-30, and 32-38 have been cancelled without prejudice to their subsequent reintroduction into this application or their introduction into a related application. Upon entry of this paper, claims 1-8, 10-12, 14-23, 28, and 31 will be pending and under consideration.

Claims 12 and 23 have been amended to incorporate the limitations of claims 13 and 24, respectively, which have been cancelled. Support for these amendments can be found throughout the application as filed, for example, in claims 13 and 24 in the application as filed. In addition, claims have been amended to delete multiple dependencies and to amend grammar, including grammar relating to antecedent basis. Applicants believe that these claim amendments introduce no new matter.

The Office's Notification of Missing Requirements indicates that a Sequence Listing is required for completion of the filing requirements associated with this application. However, Applicants believe that this application does not contain a nucleotide or amino acid sequence as defined by 37 CFR § 1.821(a) and therefore does not require submission of a Sequence Listing. Upon receiving the Notification, the undersigned attorney phoned Mr. Christopher Lowe, SPE in Art Unit 1600, who reviewed the application and confirmed that a Sequence Listing is not required for this application. Accordingly, Applicants respectfully request that this requirement be withdrawn.

**Conclusion**

The Office is invited to contact the undersigned attorney to discuss any matters relating to the application. Early favorable action is respectfully solicited.

Dated: September 10, 2007

Respectfully submitted,

By



Randall D. Morin

Registration No.: 58,312  
GOODWIN PROCTER LLP  
Exchange Place  
Boston, Massachusetts 02109  
617.570.1657  
Attorney for Applicant